314 related articles for article (PubMed ID: 33991326)
1. Pharmacokinetics and Comparative Bioavailability of Apomorphine Sublingual Film and Subcutaneous Apomorphine Formulations in Patients with Parkinson's Disease and "OFF" Episodes: Results of a Randomized, Three-Way Crossover, Open-Label Study.
Agbo F; Isaacson SH; Gil R; Chiu YY; Brantley SJ; Bhargava P; Navia B
Neurol Ther; 2021 Dec; 10(2):693-709. PubMed ID: 33991326
[TBL] [Abstract][Full Text] [Related]
2. Apomorphine Sublingual Film Compared with Subcutaneous Apomorphine for OFF Episodes in Parkinson's Disease: An Open-Label, Randomized, Crossover Study.
Stocchi F; Rascol O; Poewe W; Chaudhuri KR; Kassubek J; Lopez Manzanares L; Zhang Y; Bowling A; Pappert E; Wu S;
J Parkinsons Dis; 2023; 13(8):1329-1342. PubMed ID: 37980683
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Apomorphine Sublingual Film as an "On-Demand" Treatment for "OFF" Episodes in Patients with Parkinson's Disease.
Thach A; Kirson N; Zichlin ML; Dieye I; Pappert E; Williams GR
J Health Econ Outcomes Res; 2021; 8(2):82-92. PubMed ID: 35178465
[No Abstract] [Full Text] [Related]
4. Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson's disease.
Agbo F; Crass RL; Chiu YY; Chapel S; Galluppi G; Blum D; Navia B
Clin Transl Sci; 2021 Jul; 14(4):1464-1475. PubMed ID: 33650272
[TBL] [Abstract][Full Text] [Related]
5. Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and "OFF" episodes.
Hui JS; Fox SH; Neeson W; Bhargava P; Pappert E; Blum D; Navia B;
Parkinsonism Relat Disord; 2020 Oct; 79():110-116. PubMed ID: 32927285
[TBL] [Abstract][Full Text] [Related]
6. LC-MS/MS simultaneous quantification of apomorphine and its major metabolites in human plasma: Application to clinical comparative bioavailability evaluation for the apomorphine sublingual film and a subcutaneous product.
Chen YL; Shi L; Agbo F; Yong SH; Tan PS; Ngounou Wetie AG
J Pharm Biomed Anal; 2020 Oct; 190():113493. PubMed ID: 32795778
[TBL] [Abstract][Full Text] [Related]
7. Feasibility of home dose optimization of apomorphine sublingual film in Parkinson's disease patients with OFF episodes: results from the dose-optimization phase of an open-label, randomized crossover study.
Kassubek J; Stocchi F; Martinez EB; Pahwa R; Ondo W; Zhang Y; Bowling A; Pappert E; Isaacson S; Wu S;
Ther Adv Neurol Disord; 2023; 16():17562864231209240. PubMed ID: 37954918
[TBL] [Abstract][Full Text] [Related]
8. ND0701, A Novel Formulation of Apomorphine for Subcutaneous Infusion, in Comparison to a Commercial Apomorphine Formulation: 28-Day Pharmacokinetic Study in Minipigs and a Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Relative Bioavailability.
Ramot Y; Nyska A; Adar L; Durlach C; Fishelovitch D; Sacco G; Manno RA; Oren S; Perlstein I; Yacobi-Zeevi O
CNS Drugs; 2018 May; 32(5):443-454. PubMed ID: 29637529
[TBL] [Abstract][Full Text] [Related]
9. Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson's disease complicated by OFF episodes: a phase 3, open-label study.
Kassubek J; Factor SA; Balaguer E; Schwarz J; Chaudhuri KR; Isaacson SH; Wu S; Denecke Muhr C; Kulisevsky J
J Neurol; 2024 Jun; 271(6):3554-3570. PubMed ID: 38546829
[TBL] [Abstract][Full Text] [Related]
10. Dose optimization of apomorphine sublingual film for treating "OFF" episodes in Parkinson's disease.
Olanow CW; Stocchi F; Peckham EL; De Pandis MF; Sciarappa K; Navia B
Parkinsonism Relat Disord; 2021 Dec; 93():27-30. PubMed ID: 34763305
[TBL] [Abstract][Full Text] [Related]
11. Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson's disease 'OFF' episodes.
Thach A; Zichlin ML; Kirson N; Yang K; Gaburo K; Pappert E; Mehta D; Williams GR
J Comp Eff Res; 2022 Mar; 11(4):285-295. PubMed ID: 35068168
[No Abstract] [Full Text] [Related]
12. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
[TBL] [Abstract][Full Text] [Related]
13. Clinical trial evaluating apomorphine oromucosal solution in Parkinson's disease patients.
Thijssen E; Tuk B; Cakici M; van Velze V; Klaassen E; Merkus F; van Laar T; Kremer P; Groeneveld GJ
Clin Transl Sci; 2024 May; 17(5):e13796. PubMed ID: 38712716
[TBL] [Abstract][Full Text] [Related]
14. A Randomized Thorough QT Study of Apomorphine Sublingual Film in Patients With Parkinson's Disease.
Stocchi F; Peckham EL; De Pandis MF; Sciarappa K; Kleiman R; Agbo F; Olanow CW; Blum D; Navia B
Clin Pharmacol Drug Dev; 2022 Sep; 11(9):1068-1077. PubMed ID: 35899977
[TBL] [Abstract][Full Text] [Related]
15. Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson's disease.
Nasser A; Gomeni R; Ceresoli-Borroni G; Xie L; Busse GD; Melyan Z; Rubin J
J Pharmacokinet Pharmacodyn; 2024 Apr; ():. PubMed ID: 38578533
[TBL] [Abstract][Full Text] [Related]
16. Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study.
Montastruc JL; Rascol O; Senard JM; Gualano V; Bagheri H; Houin G; Lees A; Rascol A
Clin Neuropharmacol; 1991 Oct; 14(5):432-7. PubMed ID: 1742752
[TBL] [Abstract][Full Text] [Related]
17. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
18. A Randomized Trial Assessing the Safety, Pharmacokinetics, and Efficacy During Morning Off of AZ-009.
Thijssen E; den Heijer J; Puibert D; Moss L; Lei M; Hasegawa D; Keum K; Mochel K; Ezzeldin Sharaf M; Alfredson T; Zeng W; van Brummelen E; Naranda T; Groeneveld GJ
Mov Disord; 2022 Apr; 37(4):790-798. PubMed ID: 35048423
[TBL] [Abstract][Full Text] [Related]
19. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.
Hauser RA; Olanow CW; Dzyngel B; Bilbault T; Shill H; Isaacson S; Dubow J; Agro A
Mov Disord; 2016 Sep; 31(9):1366-72. PubMed ID: 27430123
[TBL] [Abstract][Full Text] [Related]
20. A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults.
Munjal S; Gautam A; Offman E; Brand-Schieber E; Allenby K; Fisher DM
Headache; 2016 Oct; 56(9):1455-1465. PubMed ID: 27613076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
